Cost-utility of angiotensin-converting enzyme inhibitor-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly Australians considering diabetes as comorbidity

Medicine
Enayet K ChowdhurySecond Australian National Blood Pressure Study Management Committee

Abstract

The objective of this study was to examine the cost-effectiveness of angiotensin-converting enzyme inhibitor (ACEI)-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly Australians considering diabetes as an outcome along with cardiovascular outcomes from the Australian government's perspective.We used a cost-utility analysis to estimate the incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) gained. Data on cardiovascular events and new onset of diabetes were used from the Second Australian National Blood Pressure Study, a randomized clinical trial comparing diuretic-based (hydrochlorothiazide) versus ACEI-based (enalapril) treatment in 6083 elderly (age ≥65 years) hypertensive patients over a median 4.1-year period. For this economic analysis, the total study population was stratified into 2 groups. Group A was restricted to participants diabetes free at baseline (n = 5642); group B was restricted to participants with preexisting diabetes mellitus (type 1 or type 2) at baseline (n = 441). Data on utility scores for different events were used from available published literatures; whereas, treatment and adverse event management costs were calculated from direc...Continue Reading

References

Jul 9, 1994·Lancet·P K Whelton
May 20, 1999·Hypertension·M H AldermanS Madhavan
Apr 17, 2001·Hypertension·J R SowersE D Frohlich
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Feb 14, 2003·The New England Journal of Medicine·Lindon M H WingUNKNOWN Second Australian National Blood Pressure Study Group
Feb 26, 2003·Circulation·Andre LamyUNKNOWN Heart Outcomes Prevention Evaluation Investigators
May 20, 2003·PharmacoEconomics·Alain J NordmannAllan S Detsky
Nov 15, 2003·Lancet·Fiona Turnbull, UNKNOWN Blood Pressure Lowering Treatment Trialists' Collaboration
Sep 29, 2004·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Johan L Severens, Richard J Milne
Dec 28, 2004·The American Journal of Cardiology·John B KostisUNKNOWN SHEP Collaborative Research Group
Jan 18, 2005·Lancet·Patricia M KearneyJiang He
Jul 28, 2005·JAMA : the Journal of the American Medical Association·Donald M Lloyd-JonesDaniel Levy
Dec 7, 2005·Journal of Hypertension·Giuseppe ManciaAlberto Zanchetti
Apr 29, 2006·Diabetes Care·Eric N TaylorGary C Curhan
Apr 2, 2008·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Anthony H HarrisEmily Walkom
Feb 23, 2010·Clinical Therapeutics·Zanfina AdemiUNKNOWN REACH Registry Investigators
Jan 26, 2011·Circulation·Paul A HeidenreichUNKNOWN Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research
Sep 21, 2013·American Journal of Hypertension·Steven M Smith, Jonathan D Campbell
Nov 20, 2013·American Journal of Hypertension·Enayet K ChowdhuryUNKNOWN Second Australian National Blood Pressure Study Management Committee

❮ Previous
Next ❯

Citations

Oct 27, 2017·The Journal of Clinical Hypertension·Zimeng LiQing Wang
Jul 25, 2020·Expert Review of Pharmacoeconomics & Outcomes Research·Xin WangSusan Abughosh
Aug 14, 2018·International Psychogeriatrics·Enayet K ChowdhuryChristopher M Reid

❮ Previous
Next ❯

Software Mentioned

Stata
Excel
RISK

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.